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NEMO Hind Lal, Kyle L. Kolaja, Thomas Force
Protein kinases are the most frequently mutated genes in the cancer genome, making them
attractive therapeutic targets for drug design. However, the use of kinase inhibitors (KIs) has
been associated with toxicities to the heart and vasculature. Lal and colleagues discuss the role
of protein kinases in normal cellular function and the mutations that occur in cancer. KIs can
cause cardiotoxicity through on-target mechanisms, where the kinase that is targeted in the
cancer also provides an important function in the heart and/or vasculature. KIs may also cause
cardiac problems through off-target mechanisms, where nonselective inhibition of a kinase not
targeted by the KI is responsible for the cardiotoxicity.SPECIAL ARTICLE SPECIAL ARTICLE275The Magnitude and Nature of Unfunded Published Cardiovascular ResearchTuan V. Mai, Donna L. Agan, Paul Clopton, Glenn Collins, Anthony N. DeMaria
Mai and colleagues surveyed nearly 1,000 authors who recently published papers in the JACC
to determine the extent, type, and sources of funding for published cardiovascular research.
The percentage of authors who were fully funded was 26%, partially funded was 44%, and
those without any direct funding was 30%. Most funding came from government (42%) and
industry (35%). Authors who were 50 years of age or older, from the United States, had PhD
degrees, doing basic as well as clinical research, or studying genetics/genomics had
significantly more sources of funding and types of support. These results show that much of
the published cardiovascular research is currently being performed without direct financial
support and this may limit the growth in medical knowledge.(continued on page A-27)
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282orse Outcomes With Incomplete Revascularization:
Data From the SYNTAX TrialVasim Farooq, Patrick W. Serruys, Hector M. Garcia-Garcia, Yaojun Zhang, Christos V. Bourantas,
David R. Holmes, Michael Mack, Ted Feldman, Marie-Claude Morice, Elisabeth Ståhle, Stefan James,
Antonio Colombo, Roberto Diletti, Michail I. Papafaklis, Ton de Vries, Marie-angèle Morel,
Gerrit Anne van Es, Friedrich W. Mohr, Keith D. Dawkins, Arie-Pieter Kappetein, Georgios Sianos,
Eric Boersma
Farooq and colleagues evaluated the clinical significance of angiographic complete
revascularization (CR) or incomplete revascularization (ICR), after percutaneous coronary
intervention (PCI) or coronary artery bypass graft (CABG) surgery in the ‘all-comers’
SYNTAX trial. While SYNTAX was a randomized trial of PCI versus CABG, data was also
collected on patients who were not eligible for both procedures and is included in these
results. CR, defined as revascularization of all vessels 1.5 mm with a 50% stenosis, was
achieved in 53% of the PCI arm and 67% in the CABG arm. ICR was associated with
higher 4-year mortality rates as well as other cardiac endpoints in both the PCI and CABG
cohorts. These results show that ICR is predictive of worse long-term clinical outcomes.CORONARY REVASCULARIZATION295Use of Preventive Medications After CABG Surgery Compared With PCIMark A. Hlatky, Matthew D. Solomon, David Shilane, Thomas K. Leong, Ralph Brindis, Alan S. Go
Hlatky and colleagues sought to compare the use of secondary preventive medications after
coronary artery bypass (CABG) surgery or percutaneous coronary intervention (PCI). Data
was culled from a large integrated health care delivery system for patients who underwent
either CABG or PCI regarding their subsequent dispensed prescriptions. CABG patients
were more likely than patients receiving PCI to not fill a prescription for a statin or for an
angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, but similar proportions
never filled a prescription for a beta-blocker. CABG patients had lower medication possession
ratios than patients receiving PCI. These results suggest that there is a need for patient
education regarding the benefits of secondary prevention after a revascularization procedure.(continued on page A-30)
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302ypass Grafting With the Internal Thoracic Artery
to the LAD Improves Outcomes in Redo CABG PatientsJoseph F. Sabik III, Sajjad Raza, Eugene H. Blackstone, Penny L. Houghtaling, Bruce W. Lytle
Sabik and colleagues sought to determine if left internal thoracic artery (LITA) grafting of
the left anterior descending (LAD) at reoperative coronary artery bypass grafting (CABG)
improves patient outcomes compared to saphenous vein grafting (SVG). Reoperative CABG
was performed in 3,473 patients who did not receive a LITA during their primary CABG
and whose anterior myocardium (LAD) was at risk at reoperation. Unadjusted hospital
mortality was 2.2% and 6.5% in the LITA and SVG groups, respectively. After 20 years,
LITA patients had an absolute mortality risk reduction of 6.0%. These results confirm that in
patients with a previous CABG, LITA-to-LAD grafting at reoperation is safe and confers a
risk-adjusted survival advantage.Editorial Comment: Robert H. Jones, page 311HEART FAILURE313The HeartMate II Risk Score Predicts Survival After LVADJennifer Cowger, Kartik Sundareswaran, Joseph G. Rogers, Soon J. Park, Francis D. Pagani, Geetha Bhat,
Brian Jaski, David J. Farrar, Mark S. Slaughter
Cowger and colleagues sought to derive and validate a model to predict survival in candidates
for HeartMate II (HM II) left ventricular assist device (LVAD) support. Patients enrolled
into the HM II bridge to transplantation and destination therapy trials were randomly
divided into derivation and validation cohorts. Preoperative candidate predictors of 90 day
mortality were examined and using logistic regression the HMII risk score (HMRS) was
derived. Risk factors for mortality included age, hypoalbuminemia, renal dysfunction,
coagulopathy, and implantation at less experienced centers. Mortality in the low, medium,
and high HMRS groups was 4%, 16%, and 29% in the derivation cohort and similar in the
validation cohort respectively. The HMRS may be useful for mortality risk stratification in
HMII candidates.
Editorial Comment: Wayne C. Levy, page 322(continued on page A-32)
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325rognosis Among Healthy Individuals
Discharged With a Primary Diagnosis of SyncopeMartin Huth Ruwald, Morten Lock Hansen, Morten Lamberts, Carolina Malta Hansen, Michael Vinther,
Lars Køber, Christian Torp-Pedersen, Jim Hansen, Gunnar Hilmar Gislason
Ruwald and colleagues examined the risk of major cardiac adverse events and death in a
nationwide cohort of healthy patients admitted for syncope. Patients without prior
comorbidity admitted for syncope in Denmark were matched with healthy controls.
Multivariable Cox regression analysis demonstrated significantly increased risk of all-cause
mortality (hazard ratio [HR]: 1.06), cardiovascular hospitalization event rate (HR: 1.74), and
a HR of 5.52 for pacemaker or implantable cardioverter-defibrillator implantation.
Presumably healthy individuals who present with syncope are at higher risk for all-cause
mortality during long-term follow-up.Editorial Comment: Robert S. Sheldon, page 333HYPERTENSION335Dietary Sodium Restriction Reverses Vascular Endothelial DysfunctionKristen L. Jablonski, Matthew L. Racine, Candace J. Geolfos, Phillip E. Gates, Michel Chonchol,
Matthew B. McQueen, Douglas R. Seals
This study determined the efficacy of dietary sodium restriction for improving vascular
endothelial dysfunction in adults with moderately elevated systolic blood pressure. Seventeen
subjects completed a randomized, crossover study of 4 weeks of low sodium intake and
4 weeks of normal sodium intake. Conduit (brachial artery flow-mediated dilation) and
resistance artery (forearm blood flow responses to acetylcholine) were better following the
low-sodium diet. These results show that dietary sodium restriction induces “vascular
protection” beyond that attributable to its blood pressure-lowering effects.
Editorial Comment: David S. Celermajer, Bruce Neal, page 344(continued on page A-34)
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Barbara Szechtman, Robert Weintraub, Maureen Andrew, Paul Monagle, for the Fontan Anticoagulation
Study Group
A randomized controlled trial of acetylsalicylic acid versus warfarin for thromboprophylaxis
after the Fontan procedure did not show a significant difference regarding thrombotic
complications. McCrindle and colleagues performed a secondary analysis to identify
thrombosis risk factors. One-third of subjects developed a thrombosis during 2.5 years of
follow-up (all venous, no arterial events). In multivariable models, factors associated with
higher risk of thrombosis were pulmonary atresia with intact ventricular septum, pulmonary
artery distortion, higher pre-operative unconjugated bilirubin, use of central venous lines for
10 days, and lower FiO2 24 h after the procedure. More favorable thromboprophylaxis
strategies are needed given the high prevalence of thrombosis in this population.Editorial Comment: Carl L. Backer, page 357
